Nutrition 21 Inc.
4 Manhattanville Road
Purchase,
NY 10577-2197
United States - Map
Phone: 914-701-4500
Fax: 914-696-0863
Web Site: http://www.nutrition21.com
| Index Membership: | N/A | | Sector: | N/A | | Industry: | N/A | | Full Time Employees: | 20 |
|
| Nutrition 21, Inc., a nutritional bioscience company, develops, markets, and distributes proprietary and clinically substantiated nutritional supplements in the United States. The company sells Chromax branded chromium picolinate to vitamin and supplement and food manufacturers and marketers, as well as directly to retailers for use in human and animal nutrition products. It also develops and commercializes Diabetes Essentials, a proprietary, non-prescription, insulin sensitizer for people with type 2 diabetes. In addition, the company offers a portfolio of health and wellness products under the Iceland Health Maximum Strength Omega-3, Iceland Health Joint Relief, Iceland Health Advanced Memory Formula, Chromax chromium picolinate, Prescriptix Supplements, and Diabetes Essentials names. It offers its products through direct response channels, including TV infomercials, radio, print, direct mail, and Internet e-commerce, as well as through retail distribution channel. In addition, Nutrition 21, Inc. grants patent licenses to its ingredients to manufacturers and marketers of vitamin and mineral supplements. The company was founded in 1983 and is headquartered in Purchase, New York. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Michael A. Zeher , 61
Chief Exec. Officer, Pres |
$
162.00K | N/A | Mr. Alan J. Kirschbaum , 64
Chief Financial Officer, Principal Accounting Officer, VP of Fin. and Treasury |
N/A
| N/A | Mr. Benjamin T. Sporn , 71
Sr. VP, Sec. and Gen. Counsel |
N/A
| N/A | Mrs. Pam McWilliams ,
VP and Gen. Mang. of Direct Response |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.27% Nasdaq 
Profile
